There are over 80 autoimmune diseases that can occur if the immune system mistakenly attacks and damages the body’s healthy tissues. Normally, the immune system helps protect the body from harmful pathogens like bacteria and viruses. Diagnostic tests can detect autoimmune diseases early, leading to early treatment and improved patient outcomes. Early diagnosis also helps reduce the financial burden of autoimmune diseases.
Stress, genetic mutations, unhealthy eating habits, and environmental factors are among the leading causes of autoimmune diseases. According to the American Autoimmune Related Disease Association, around 50 million people in the U.S. have autoimmune diseases, with associated expenditures reaching USD 86 billion annually. Autoimmune disease testing is expected to increase due to the rising prevalence of these diseases. For instance, according to Lancet Diabetes & Endocrinology, in 2021, around 8.4 million people were affected with type-1 diabetes (one of the most common autoimmune diseases) globally. This number is estimated to increase to 13.5–17.4 million people by 2040. Also, as of 2022, around 1-1.5% of the European population (7 million) had celiac disease. (Source: European Parliament). Similarly, as of 2020, around 44 people per 100,000 were affected with multiple sclerosis globally (Source: MS Atlas).
Awareness regarding the diagnosis and treatment of autoimmune diseases is rising, mainly due to initiatives undertaken by several public and private organizations. For instance, every year in March, the Autoimmune Association (U.S.) conducts events and campaigns for the entire month to raise awareness, spread information, and increase knowledge about autoimmune disorders. The early diagnosis of autoimmune diseases is crucial in reducing disability, morbidity, and mortality among people. Hence, the rising awareness regarding autoimmune diseases is driving the adoption of diagnostic products for autoimmune disease testing.
Research is vital in developing diagnostic and therapeutic technologies for autoimmune disease diagnosis and monitoring. Research also helps in increasing medical professionals’ understanding of these diseases. Celiac disease is one of the most common autoimmune diseases globally. Increasing funding and investments for research on autoimmune diseases are expected to generate growth opportunities for the players operating in this market. For instance, according to the National Institutes of Health (NIH) (U.S.), in 2021, research spending for celiac disease reached USD 9 million. Moreover, in 2021, the National Health and Medical Research Council (NHMRC) (Australia), a government entity, awarded USD 1.1 million to a researcher to carry out research activities to understand the symptoms of the disease and improve health outcomes related to the disease.
Sufficient financial support in the form of funding and investments enables diagnostic companies and research institutions to focus on developing cutting-edge and progressive diagnostic technologies with enhanced precision, sensitivity, and specificity and exploring novel biomarkers and diagnostic instruments.
Furthermore, introducing new diagnostic tests into the market requires extensive clinical trials confirming their effectiveness and safety. These trials are typically costly and time intensive. Adequate funding is necessary to carry out these trials, fulfill the regulatory criteria set by health authorities like the FDA (U.S. Food and Drug Administration) and the European Medicines Agency (EMA), and secure approvals.
Allocating resources to marketing and educational campaigns is vital for promoting awareness regarding the significance of early detection of autoimmune diseases and improving access to advanced diagnostic tools. Thus, initiatives such as investments and funding can drive the adoption of diagnostic tests, improving patient outcomes.
Therefore, the increasing prevalence of autoimmune diseases, favorable initiatives to raise awareness regarding autoimmune diseases, and growing funding for autoimmune diseases are driving the adoption of autoimmune disease diagnostics. According to Meticulous Research®, the global autoimmune disease diagnostics market is expected to register a CAGR of 7.2% to reach $9.84 billion by 2030.
Access Full Report Here @ https://www.meticulousresearch.com/product/autoimmune-disease-diagnostics-market-5405